Abstract
Radiochemotherapy represents the cornerstone of the treatment for patients affected by locally advanced non small cell lung cancer. Nevertheless, to date there is no agreement concerning how the standard therapy is and many questions are still open. Two timing modalities have been proposed to combine chemotherapy and radiotherapy: after many phase II/III have tested concurrent or sequential approach, concurrent radiochemotherapy is today considered as the treatment of choice, despite the role of induction or consolidation chemotherapy is still unclear. Cisplatin alone or in combination is considered as the reference drug in combination with chemotherapy, but in the last decades, many trials have demonstrated that new-generation drugs, which are routinely used in metastatic disease, may be used during radiotherapy and may enhance its tumor control rate, frequently having a radiosentizing power. Finally, in the era of molecular biomarkers and target therapies, new approaches could dramatically change the physicians view about the drug choice giving the opportunity of a tailored therapy customized on the single patient also in the treatment of locally advanced non-small cell lung cancer.
Keywords: Non-small cell lung cancer, chemotherapy, radiotherapy, target therapy, radiosensitizing agents
Current Drug Therapy
Title: Radiochemotherapy for Non Small Cell Lung Cancer
Volume: 5 Issue: 3
Author(s): Orazio Caffo and Viviana Murgia
Affiliation:
Keywords: Non-small cell lung cancer, chemotherapy, radiotherapy, target therapy, radiosensitizing agents
Abstract: Radiochemotherapy represents the cornerstone of the treatment for patients affected by locally advanced non small cell lung cancer. Nevertheless, to date there is no agreement concerning how the standard therapy is and many questions are still open. Two timing modalities have been proposed to combine chemotherapy and radiotherapy: after many phase II/III have tested concurrent or sequential approach, concurrent radiochemotherapy is today considered as the treatment of choice, despite the role of induction or consolidation chemotherapy is still unclear. Cisplatin alone or in combination is considered as the reference drug in combination with chemotherapy, but in the last decades, many trials have demonstrated that new-generation drugs, which are routinely used in metastatic disease, may be used during radiotherapy and may enhance its tumor control rate, frequently having a radiosentizing power. Finally, in the era of molecular biomarkers and target therapies, new approaches could dramatically change the physicians view about the drug choice giving the opportunity of a tailored therapy customized on the single patient also in the treatment of locally advanced non-small cell lung cancer.
Export Options
About this article
Cite this article as:
Caffo Orazio and Murgia Viviana, Radiochemotherapy for Non Small Cell Lung Cancer, Current Drug Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157488510791561084
DOI https://dx.doi.org/10.2174/157488510791561084 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry New Drugs for Follicular Lymphoma in Older Adults
Anti-Cancer Agents in Medicinal Chemistry β-Lactone Derivatives and Their Anticancer Activities: A Short Review
Current Topics in Medicinal Chemistry The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Role of Stem Cells in Normal Liver and Cancer
Anti-Cancer Agents in Medicinal Chemistry HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation
Current Pharmacogenomics Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Evaluation of Oxidative Stress Biomarkers in Brain Metastatic and Non-Metastatic Lung Cancer Patients with Different Cell Types
Anti-Cancer Agents in Medicinal Chemistry Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know
Anti-Cancer Agents in Medicinal Chemistry Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets